356 results on '"Shah, Mithun Vinod"'
Search Results
2. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
3. Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms
4. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance
5. The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant
6. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
7. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
8. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study
9. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
10. Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms
11. Impact of second primary malignancy postautologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
12. Autoimmune manifestations in STAG2-mutated myeloid neoplasms
13. Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T.
14. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
15. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
16. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval
17. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms
18. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
19. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
20. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms
21. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system
22. Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.
23. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia
24. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma
25. Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers
26. Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy
27. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
28. Impact of Second Primary Malignancy Post–Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis
29. The Mutational Landscape in Chronic Myelomonocytic Leukemia and Its Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for Blood and Marrow Transplantation Research (CIBMTR) Analysis
30. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis
31. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival
32. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
33. Impact of Genetic Targets on Cancer Therapy in Acute Myelogenous Leukemia
34. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
35. Large Granular Lymphocyte Leukemia – From Molecular Pathogenesis to Targeted Therapy
36. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms
37. Comparison between GATA2 and DDX41-mutated myeloid neoplasms
38. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
39. Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.
40. Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.
41. Characteristics and prognosis of DDX41- and GATA2-mutated myeloid neoplasms.
42. Characteristics and prognosis of mutated STAG2 myeloid neoplasms.
43. Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms
44. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
45. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis
46. Network Model of Survival Signaling in Large Granular Lymphocyte Leukemia
47. A population‐based study of acute panmyelosis with myelofibrosis in the United States: 2004–2015
48. Genetic features and clinical outcomes of patients with isolated and comutatedDDX41-mutated myeloid neoplasms
49. Bilateral Foot Gangrene
50. A population‐based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.